fluconazole has been researched along with Cleft Palate in 4 studies
Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.
fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.
Cleft Palate: Congenital fissure of the soft and/or hard palate, due to faulty fusion.
Excerpt | Relevance | Reference |
---|---|---|
"To examine the risk of congenital malformations associated with exposure to oral fluconazole at commonly used doses in the first trimester of pregnancy for the treatment of vulvovaginal candidiasis." | 3.96 | Oral fluconazole use in the first trimester and risk of congenital malformations: population based cohort study. ( Bateman, BT; Gray, KJ; Hernandez-Diaz, S; Huybrechts, KF; Mogun, H; Straub, L; Zhu, Y, 2020) |
"Fluconazole (FCZ) is an antifungal bis-triazole with potent inhibitory effect on the principal CYP-dependent metabolic pathway of PHT." | 2.69 | Teratological interaction between the bis-triazole antifungal agent fluconazole and the anticonvulsant drug phenytoin. ( Bellati, U; Di Ilio, C; Giampietro, F; Iammarrone, E; Lamonaca, D; Tiboni, GM, 1999) |
" Dose-response relationship was investigated by treating animals with 0 (vehicle), 87." | 1.33 | Murine teratology of fluconazole: evaluation of developmental phase specificity and dose dependence. ( Giampietro, F; Tiboni, GM, 2005) |
"Fluconazole (FCZ) is a potent inhibitor of the cytochrome P450 (CYP)-mediated metabolism of the anti-epileptic agent phenytoin (PHT), a well-known human and animal teratogen." | 1.32 | Additional investigation on the potentiation of phenytoin teratogenicity by fluconazole. ( Angelucci, S; Bellati, U; Di Ilio, C; Giampietro, F; Moio, P; Tiboni, GM, 2003) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (25.00) | 18.2507 |
2000's | 2 (50.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (25.00) | 2.80 |
Authors | Studies |
---|---|
Zhu, Y | 1 |
Bateman, BT | 1 |
Gray, KJ | 1 |
Hernandez-Diaz, S | 1 |
Mogun, H | 1 |
Straub, L | 1 |
Huybrechts, KF | 1 |
Tiboni, GM | 3 |
Giampietro, F | 3 |
Angelucci, S | 1 |
Moio, P | 1 |
Bellati, U | 2 |
Di Ilio, C | 2 |
Iammarrone, E | 1 |
Lamonaca, D | 1 |
1 trial available for fluconazole and Cleft Palate
Article | Year |
---|---|
Teratological interaction between the bis-triazole antifungal agent fluconazole and the anticonvulsant drug phenytoin.
Topics: Abnormalities, Drug-Induced; Animals; Anticonvulsants; Antifungal Agents; Body Weight; Cleft Palate; | 1999 |
3 other studies available for fluconazole and Cleft Palate
Article | Year |
---|---|
Oral fluconazole use in the first trimester and risk of congenital malformations: population based cohort study.
Topics: Abnormalities, Drug-Induced; Administration, Oral; Adult; Antifungal Agents; Candidiasis, Vulvovagin | 2020 |
Additional investigation on the potentiation of phenytoin teratogenicity by fluconazole.
Topics: Animals; Chromatography, High Pressure Liquid; Cleft Palate; Dose-Response Relationship, Drug; Drug | 2003 |
Murine teratology of fluconazole: evaluation of developmental phase specificity and dose dependence.
Topics: Abnormalities, Drug-Induced; Alcian Blue; Animals; Anthraquinones; Antifungal Agents; Body Weight; C | 2005 |